| Abstrakt: |
Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization or death within 30 days as compared with untreated controls previously uninfected and nonhospitalized. Methods We used a matched cohort design using inverse probability of treatment weight (IPTW). Individuals prescribed NMV/r within 3 days of COVID-19 diagnosis were compared with IPTW-based untreated controls. Variables for IPTW included age, race, sex, body mass index, geographic location, vaccination status, and multiple comorbidities. Additional analyses were conducted on NMV/r-treated and propensity score–matched untreated controls. Results Among 7615 individuals prescribed NMV/r and 62 077 controls identified between 1 January 2022 and 25 February 2023, the risk of hospitalization/death was lower among NMV/r-treated persons vs untreated controls (243 vs 3468 events; absolute risk difference [ARD], −2.36 [95% CI, −2.57 to −2.14]). The difference was significant for those >60 and ≤60 years old (ARD, −3.86 [95% CI, −4.19 to −3.54] vs −0.27 [95% CI, −0.51 to −0.03]) and for persons asymptomatic and symptomatic (ARD, −7.09 [95% CI, −7.62 to −6.55] vs −1.46 [95% CI, −1.66 to −1.25]). Significant benefit was observed among individuals unvaccinated and vaccinated, with or without a booster dose. Conclusions NMV/r is associated with a significant reduction in 30-day hospitalization or death among individuals previously uninfected and nonhospitalized. [ABSTRACT FROM AUTHOR] |
